Sanofi’s decision to find another partner to take over and commercialize efpeglenatide (SAR439977), which it had licensed in from Hanmi Pharmaceutical Co. Ltd., is an “optimal strategy” for the continued development and eventual sale of the long-acting GLP-1 agonist for type 2 diabetes, the South Korean pharma firm has said.
The two companies will continue to closely discuss the matter to keep on track a plan to file for the...